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Background: Malignancy is a potential comorbidity in patients with systemic lupus erythematosus (SLE).
However, risk by malignancy type remains to be fully elucidated. We evaluated the risk of malignancy type
in SLE patients in a systematic review and meta-analysis.
Methods: MEDLINE and EMBASE were searched from inception to July 2018 to identify observational studies
that evaluated malignancy risk in adult SLE patients compared with the general population. Random-effects
models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs). Heterogeneity was
quantified using the I2 test.
Findings: Forty-one studies reporting on 40 malignancies (one overall, 39 site-specific) were included in the
meta-analysis. The pooled RR for all malignancies from 3694 events across 80 833 patients was 1.18 (95% CI:
1.001.38). The risk of 24 site-specific malignancies (62%) was increased in SLE patients. For malignancies
with 6 studies, non-Hodgkin lymphoma and Hodgkin lymphoma risk was increased >3-fold; myeloma and
liver >2-fold; cervical, lung, bladder, and thyroid 1.5-fold; stomach and brain >1.3-fold. The risk of four
malignancies (breast, uterine, melanoma, prostate) was decreased, whereas risk of 11 other malignancies did
not differ between SLE patients and the general population. Heterogeneity ranged between 0% and 96%, and
63% were non-significant.
Interpretation: The risk of overall and some site-specific malignancies is increased in SLE compared with the
general population. However, the risk for some site-specific malignancies is decreased or did not differ. Fur-
ther examination of risk profiles and SLE patient phenotypes may support guidelines aimed at reducing
malignancy risk.
Funding: AstraZeneca.
Systematic review registration: PROSPERO number: CRD42018110433







c. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Systemic lupus erythematosus (SLE) is a complex and chronic
autoimmune disorder, affecting multiple organ systems with variableseverity. SLE is characterised by intermittent, unpredictable flares
and is associated with irreversible organ damage, resulting in a high
rate of disability [1]. SLE is associated with multiple comorbidities,
including specific cancer types [2-10], which adds to the challenge in
managing SLE [11].
Previous meta-analyses, evaluating various malignancies, identi-
fied an increased risk of some malignancy types in SLE [9,10]. How-
ever, these meta-analyses did not account for overlapping study
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the international cohort study of cancer in SLE [12], some patient
populations may have been included more than once, limiting the
interpretation of the findings. Previous meta-analyses have reported
few sensitivity analyses. To the best of our knowledge, there are cur-
rently no meta-analyses that include all cancer types for which there
are available data and exclude potential overlapping SLE populations
to elucidate the appropriate risk.
The objective of this study was to evaluate the risk of all malig-
nancies in patients with SLE compared with the general population.
This study supports and extends the growing evidence on risk of vari-
ous cancers in patients with SLE.
2. Methods
2.1. Search strategy
This study was conducted in accordance with the Meta-analysis
Of Observational Studies in Epidemiology (MOOSE) and the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines for conducting and reporting systematic reviews [13,14].
The study protocol was prepared and published via the international
prospective register of systematic reviews, PROSPERO
(#CRD42018110433). Searches for full-text reports containing origi-
nal data were run in Ovid MEDLINE and EMBASE from inception until
July 2018 (Supplementary Table S1). We also searched article refer-
ence lists and contacted experts.
2.2. Eligibility criteria
Full publications of observational studies (cohort, cross-sectional
studies) published in English, reporting the risk of malignancy in
adult patients with SLE compared with a general population and/or
healthy controls, were included. SLE diagnosis was confirmed using
International Classification of Diseases (ICD) codes, American College
of Rheumatology (ACR) criteria, or clinician review/diagnosis [15,16].
The outcomes evaluated included fatal or non-fatal malignancies.
Studies were included if they reported one of the following relative
risk measures: hazard ratio, rate ratio, risk ratio, odds ratio, incidence
rate ratio, proportionate morbidity ratio, standardised mortality rate,
or standardised incidence rate with 95% confidence intervals (CIs).
Abstracts of unpublished studies were excluded.
2.3. Screening and abstraction process
Two-stage screening (title/abstract and full-text), data extraction,
and risk of bias assessment were performed independently by two
reviewers (NP and LN); disagreement was resolved by consensus
involving a third reviewer (JL). Studies that met the eligibility criteria
and reported original data were included in the review. Data on study
characteristics and the effect measure for outcomes of interest (fatal
and non-fatal events) were extracted.
2.4. Risk of bias assessment
Studies were classified as having low, moderate, or high risk of
bias based on results from the Newcastle-Ottawa Scale [17] and an
SLE-specific 12-point scale [18] (Supplementary Tables S2 and S3).
Studies were classified as having low risk of bias if they scored 3/4
for selection, 1/2 for comparability, 3/3 for outcome domains of the
Newcastle-Ottawa Scale, and 8 on the 12-point scale.
2.5. Statistical analysis
We grouped malignancy outcomes and conducted a meta-analysis
in which 2 studies reported usable data that could be synthesisedquantitatively. For malignancy outcomes with 2 studies reporting
findings from overlapping populations, one study was selected for
inclusion based on quality, population size, and length.
Hazard ratios, rate ratios, risk ratios, odds ratios, incidence rate
ratio, proportionate morbidity ratios, standardised mortality rates, or
standardised incidence rates were considered as equal estimates
assuming rare occurrence [19] and are referred to as risk ratio (RR)
throughout this report. The most adjusted RR was used in the meta-
analysis. A DerSimonian and Laird [20] random-effects model was fit-
ted to calculate the pooled RR and 95% CIs for all outcomes.
Heterogeneity was measured using the Cochran's Q statistic (sta-
tistical significance set at p<0.10) and using the I2 test. Publication
bias was assessed using funnel plots and the Egger’s test [21].
Robustness of pooled estimates was assessed using the leave1out
function [22], which examined the effect of removing individual
studies. Sensitivity analyses were performed when >2 studies and
relevant data were available, including for least-adjusted analysis,
studies published during or after 2014, studies published before
2014, studies reporting non-fatal/fatal events, studies reporting non-
fatal events, studies with low risk of bias, and studies stratified by
geographical location (Europe, North America, or Asia). All analyses
were conducted in R version 3.5.1 using the packages metafor and
forestplot.
2.6. Data sharing
Data are available upon reasonable request (data underlying the
findings described in this manuscript may be obtained in accordance
with AstraZeneca’s data sharing policy described at https://astrazene
cagrouptrials.pharmacm.com/ST/Submission/Disclosure).
3. Results
The literature search of MEDLINE and EMBASE identified 3042
records, with 2544 articles remaining after removal of duplicates. Of
these, 2437 were excluded after screening titles and abstracts. Of 107
articles retained, 56 publications were excluded after full-text review.
Thus, 51 publications were identified as eligible for inclusion in this
analysis (Figure 1) (Supplementary Table S4 lists excluded studies
with reasons.)
Of 51 publications, 50 were cohort studies and one was a cross-
sectional study (Table 1) [23]. Studies were conducted in Europe
(n=25), Asia (n=11), North America (n=7), the Middle East (n=1), or
multiple countries (n=7). The average follow-up per study, where
reported, ranged from 2.1 to 25.7 years with the proportion of female
participants ranging from 74% to 100%. Average age, where reported,
ranged from 29 to 51 years. Risk of bias was low in 39 studies, moder-
ate in eight studies, and high in four studies (Table 1; Supplementary
Table S5).
The 51 studies included in the meta-analysis report relative risks
for 82 different malignancy outcomes. Meta-analyses were per-
formed for 40 malignancy outcomes, but not for 42 outcomes, as 39
outcomes were reported in only one study and heterogeneous find-
ings for three outcomes could not be pooled (Supplementary Table
S6).
There were 37 studies with overlapping populations. Sixteen
studies reported data included in the International lupus cohort
[12,24-38], and there were data overlaps from two studies in Den-
mark [39,40], two from Finland [41,42], 12 from Sweden [43-54], and
five from Taiwan [55-59].
When considering meta-analyses for the 40 malignancies, five of
51 studies [28,29,33,60,61] were excluded from analyses because
they could not be pooled or had overlapping populations. Overlap-
ping populations were considered on a malignancy outcome level.
Thirty-eight of the 51 studies (75%) reported more than one malig-
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Figure 1. Flow diagram of the systematic literature review process to evaluate the risk of malignancy in patients with SLE compared with the general populationSLE=systemic lupus
erythematosus.
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lapped but was included for malignancy outcomes in which over-
lapping populations were not present (Supplementary Table S7).
A further five studies, excluded from the main analysis based on
an overlapping population, were only used in sensitivity analyses
if they presented relevant data not provided by the study it over-
lapped with in the main analysis [31,34,35,37,41]. The remaining
41 studies were included in meta-analyses for 40 malignancy out-
comes, and 46 studies were included in various sensitivity analy-
ses (Table 1). Supplementary Tables S8 and S9 list all 40
malignancy outcomes by study, and Supplementary Table S7 lists
studies included in the main analysis by malignancy outcome
with reasons for exclusion.
This meta-analysis and associated sensitivity analyses report find-
ings from a minimum of 145 135 unique SLE patients on 40 malig-
nancies. In the 46 studies included in the main and/or sensitivity
analyses, malignancies were identified using ICD codes (n=23),
unspecified clinical codes/a combination of clinical records and histo-
pathology (n=18), or methods that were not reported (n=5).
Thirteen studies were eligible for inclusion in the meta-analysis
for the composite outcome ‘all malignancies’ [28,39,42,43,59,62-69].
The category ‘all malignancies’ varied widely across studies (Supple-
mentary Tables S8 and S9). SLE was associated with a marginally
increased risk of all malignancies (RR 1.18; 95% CI 1.001.38)
(Figure 2). There was high heterogeneity across studies (I2=94%;
p<0.001). Of nine sensitivity analyses, six supported an increased
malignancy risk (Table 2). Restriction to ten studies with low risk of
bias suggested a higher risk of all malignancies (RR 1.33; 95% CI
1.201.47).Of reproductive-related cancers, cervical cancer was the most fre-
quently evaluated. Fourteen studies [23,27,39,42,47,54,59,62,64-
66,68-70] demonstrated a significantly increased risk of cervical can-
cer in SLE patients compared with the general population (RR 1.66;
95% CI 1.162.36) (Figure 2). There was substantial statistical hetero-
geneity (I2=77%; p<0.001). The RR in the included studies ranged
from 0.55 (95% CI 0.390.75) [69] to 6.90 (95% CI 2.7514.44) (Sup-
plementary Figure S1) [62]. Of seven sensitivity analyses performed,
only two did not support increased risk (Table 2).
Meta-analysis identified an increased risk of vagina/vulva or
vulva-only cancer (RR 3.63; 95% CI 2.545.20; I2=64%; p=0.03) based
on five studies [27,42,56,68,69] and an increased risk of other female
genital cancer (RR 3.41; 95% CI 1.866.23; I2=0%; p=0.39) based on
two studies [39,47] (Figure 2). Of five sensitivity analyses for vagina
and/or vulva cancer, all but one supported the observed increased
risk (Table 2).
Of haematologic cancers, non-Hodgkin lymphoma (NHL) was the
second most frequently studied, with 11 eligible studies
[23,27,39,42,45,59,64-66,68,69]. SLE was significantly associated
with an increased risk compared with the general population (RR
4.32; 95% CI 3.425.47; I2=81%; p<0.001) (Figure 2). The RR ranged
from 2.44 (95% CI 2.223.34) to 15.37 (95% CI 2.9037.68). All seven
sensitivity analyses supported an increased risk of NHL.
Several other haematologic cancers (Hodgkin lymphoma
[23,27,39,46,68,69], myeloma [23,27,39,42,48,69], all haematologic
cancers [27,42,43,56,63,64], all leukaemia [27,39,43,59,69], lym-
phoma [30,58], and myeloid malignancies [58,69]) also showed a sig-
nificantly increased risk in patients with SLE compared with the
general population; RR ranged from 1.94 (95% CI 1.562.41; I2=0%;
Table 1
Characteristics of the studies included in the systematic review to assess the risk of malignancy in people with SLE compared with the general population
















Studies included in the international cohort





724; NR Fatal or non-fatal 86.6 33.3/NR Low SIR Yes
Bernatsky 2004 [33] Canada, USA, and UK 19841998, Montreal;
19851995, Chicago;
19902000, Birmingham





871; NR Fatal or non-fatal 100.0 41.0/NR Low SIR No
Bernatsky 2005 [12]
(international)
Canada, USA, UK, Iceland,
Sweden, Korea
19582000 23 lupus centres Geographically appropri-
ate matched mortality
rates
9547; NR Fatal or non-fatal 90.0 NR Low SIR Yes
Bernatsky 2005 [30] (race) Canada, USA, UK, Iceland,
Sweden, Korea
19582000 23 lupus centres US SEER Program 7312; NR Fatal or non-fatal 91.0 44.3/NR Low SIR Yes





23 lupus centres Geographically appropri-
ate matched mortality
rates
9547; NR Fatal 90.0 NR Low SMR SA




23 clinical centres Geographically appropri-
ate matched mortality
rates
9547; NR Fatal or non-fatal NR NR Low SIR No









16 409; NR Fatal or non-fatal 90.0 NR Low SIR Yes
Chun 2005 [34] South Korea 19922001 Hanyang Lupus Cohort,
Seoul
Seoul Cancer Registry 434; NR Fatal 93.1 36.1/NR High SIR SA
Cibere 2001 [24] Canada 19751994 University-based rheu-
matic disease unit
Provincial cancer statistics 297; NR Fatal or non-fatal 84.0 NR Moderate SIR Yes
Dreyer 2011 [25] Denmark 19432006 8 Danish hospital
departments
Danish Cancer Registry 576; NR Fatal or non-fatal 88.0 NR Low SIR Yes
Lu 2013 [29] Canada, USA, Korea, Den-
mark, Sweden




NR; NR Fatal or non-fatal 90.0 NR Low SIR No
Nived 2001 [35] Sweden 19811996 SLE cohort registry with
National Cancer Regis-







NR; NR Fatal or non-fatal 85.0 NR Low Standardised
morbidity rate
SA
Ragnarsson 2003 [26] Iceland 19572001 Icelandic SLE database,
Icelandic cancer
registry
Icelandic cancer registry 238; NR Fatal or non-fatal 89.5 NR Low SIR Yes
Ramsey-Goldman 1998
[37]
USA 19851995 Chicago Lupus Cohort Illinois State Cancer
Registry
616; NR Fatal or non-fatal 100.0 35.3/NR Moderate SIR SA
Sultan 2000 [36] UK 19781999 University College London
Lupus Clinic Database
Thames Cancer Registry 276; NR Fatal or non-fatal 93.5 NR Low SIR Yes
Sweeney 1995 [38] USA 19811991 University of Pittsburgh Pennsylvania Cancer Inci-
dence Registry
219; NR Fatal or non-fatal 100.0 NR High SIR Yes








































1585; NR Fatal or non-fatal 83.0 NR Low RR Yes
Sunesen 2010 [40] Denmark 19782005 Danish National Patient
Registry, Danish Cancer
Registry
Danish Cancer Registry 3612; NR Fatal or non-fatal NR NR Low SIR Yes
Finland population overlap





Finnish Cancer Registry 205; NR Fatal or non-fatal 89.0 NR Low RR SA
Tallbacka 2018 [42] Finland 19671987 Helsinki University Cen-
tral Hospital, Statistics
Finland
Finnish Cancer Registry 205; NR Fatal or non-fatal 89.0 NR Low SIR Yes
Sweden population overlap





5715; NR Fatal or non-fatal 74.0 NR Low SIR Yes






NR; NR Fatal or non-fatal NR NR Low SIR Yes





Swedish Cancer Registry 12 207; NR Fatal or non-fatal 81.7 NR Low SIR Yes
Fallah 2014 [45] (NHL) Sweden 19642010 Outpatient Registry, Pri-




Swedish Cancer Registry 12 207; NR Fatal or non-fatal 81.7 NR Low SIR Yes
Hemminki 2012 [50]
(digestive)
Sweden 19642008 Swedish Hospital Dis-
charge Register
Swedish Cancer Registry NR; NR Fatal or non-fatal NR NR Low HR/SMR Yes
Hemminki 2012 [51]
(digestive histology)
Sweden 19642008 Swedish Hospital Dis-
charge Register
Swedish Cancer Registry 5318; NR Fatal or non-fatal NR NR Low SIR Yes
Hemminki 2012 [47]
(female)
Sweden 19642008 Swedish Hospital Dis-
charge Register
Swedish Cancer Registry 5353; NR Fatal or non-fatal 100.0 NR Low SIR Yes
Hemminki 2012 [49]
(lung)
Sweden 19642008 Swedish Hospital Dis-
charge Register
Swedish Cancer Registry 7624; NR Fatal or non-fatal NR NR Low SIR Yes
Hemminki 2012 [48]
(MM)
Sweden 19642008 Swedish Hospital Dis-
charge Register
Swedish Cancer Registry 7624; NR Fatal or non-fatal NR NR Low SIR Yes
Hemminki 2013 [52]
(brain)
Sweden 19642008 Swedish Hospital Dis-
charge Register
Swedish Cancer Registry 7624; NR Fatal or non-fatal NR NR Low SIR Yes







7624; NR Fatal or non-fatal NR NR Low SIR Yes

































Wadstr€om 2017 [54] Sweden 20062012 National Patient Register,
Prescribed Drug Regis-
ter, Swedish Cancer




Same source as SLE data 4976; 29 703 Fatal or non-fatal 100.0 51.0/51.0 Moderate SIR Yes
Taiwan population overlap






8751; 87 510 Fatal or non-fatal 88.3 35.1/35.1 Low IRR Yes








11 763; NR Fatal or non-fatal 88.4 NR Low SIR Yes




Same source as SLE data 2150; 17 207 Fatal or non-fatal 77.4 NR Low HR Yes




Same source as SLE data 9349; 46 745 Fatal or non-fatal 100.0 37.3/37.1 Low SIR Yes
Yu 2016 [59] Taiwan 19972012 National Health Insurance
Research Database in
Taiwan
Same source as SLE data 15 623; NR Fatal or non-fatal 87.6 NR Low SIR Yes
Studies without population overlap
Azrielant 2017 [23] Israel NR Clalit Health Services
database
Same source as SLE data 5018; 25 090 Fatal or non-fatal 82.0 50.2/50.2 Moderate OR Yes




1052; NR Fatal or non-fatal 88.9 35.0/NR Low SIR Yes
Hidalgo-Conde 2013 [67] Spain 19892006 Hospital Universitario Vir-
gen de la Victoria,
Malaga
Same source as SLE data 175; NA Fatal or non-fatal 90.0 39.0/NR Low SIR Yes




914; NR Fatal or non-fatal 100.0 29.1/NR Low SIR Yes
Khaliq 2015 [72] USA 20072011 Medicare data Same source as SLE data 18 432; 3 651 715 Fatal or non-fatal 100.0 NR Low Incidence ratio Yes
Kim 2015 [70] USA 20012012 Wellpoint and the United
Healthcare
Same source as SLE data 14 513; 533 332 Fatal or non-fatal 100.0 47.7/50.3 Low HR Yes




gists, Norway’s Cause of
Death Registry
Norway’s Cause of Death
Registry
325; NR Fatal 90.0 NR Moderate OR No
Parikh-Patel 2008 [69] USA 19912002 Patient Discharge Dataset,
California Cancer
Registry
California Cancer Registry 30 478; NR Fatal or non-fatal 89.0 NR Moderate SIR Yes




6636 eligible; 25 111 Fatal or non-fatal 85.8 48.1/48.1 Low IRR Yes
Tarr 2007 [64] Hungary 19702004 University of Debrecen,
Debrecen
Health for All database 860; NR Fatal or non-fatal 90.0 NR Moderate SIR Yes
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for Hodgkin lymphoma. Twenty of 23 sensitivity analyses supported
an increased risk of haematologic cancer (Table 2).
SLE was associated with a significant increased risk of liver cancer
(RR 2.81; 95% CI 1.724.59; I2=64%; p=0.02) (Figure 2) in six studies
[27,39,42,44,57,69]. The RR ranged between 1.28 (95% CI 0.662.47)
and 8.00 (95% CI 2.6018.60). All four sensitivity analyses supported
an increased risk of liver cancer (Table 2).
Meta-analysis of all hepatobiliary cancers and liver/gallbladder
cancer, reported in four [12,44,59,64] and three [24,56,68] studies,
respectively, demonstrated an increased risk in patients with SLE
compared with the general population (RR 2.07; 95% CI 1.373.12;
I2=56%; p=0.08 and RR 1.83; 95% CI 1.761.90; I2=0%; p=0.76, respec-
tively) (Figure 2). All sensitivity analyses supported an increased risk
of hepatobiliary and liver/gallbladder cancers (Table 2).
Risk of lung cancer and all respiratory cancers (composite out-
come) was increased in SLE patients compared with the general pop-
ulation (RR 1.75; 95% CI 1.372.24; I2=74%; p<0.001 from nine
studies [27,39,49,59,62,64,66,68,69] and RR 1.53; 95% CI 1.112.11;
I2=78%; p=0.01 from three studies [39,43,56], respectively) (Figure 2).
The RR for lung cancer ranged between 0.48 (95% CI 0.111.23) and
3.27 (95% CI 2.065.18). Of eight sensitivity analyses performed, all
but one supported the increased risk of respiratory cancer (Table 2).
Risk of cancers of the larynx and oropharynx was increased in
patients with SLE (RR 4.21; 95% CI 1.979.03; I2=1%; p=0.36 from
three studies [26,39,43] and RR 7.35; 95% CI 1.1248.35; I2=0%;
p=0.80 from two studies [24,55]) (Figure 2).
We observed an increased risk of stomach cancer (RR 1.34; 95% CI
1.051.72; I2=0%; p=0.80) in patients with SLE in nine studies
[27,39,42,51,59,64-66,69] (Figure 2). The RR ranged between 0.60
(95% CI 0.121.74) and 1.88 (95% CI 1.212.91). Two of five sensitiv-
ity analyses supported an increased risk of stomach cancer (Table 2).
The risk of oesophagus [25,39,51,59,69], colon [25,32,38,42,51],
and anal [25,36,40,51] cancers was increased in patients with SLE
(oesophagus RR 1.73; 95% CI 1.032.89; I2=0%; p=0.73; colon RR
1.65; 95% CI 1.232.22; I2=0%; p=0.95; and anal RR 5.69; 95% CI
1.6219.94; I2=72%; p=0.02) (Figure 2). One of three sensitivity anal-
yses for oesophagus cancer and three of four sensitivity analyses for
colon cancer supported an increased cancer risk (Table 2).
The risk of several other cancers was increased in patients with
SLE, including bladder cancer [27,39,42,53,59,64,66,68,69] (RR 1.80;
95% CI 1.043.11; I2=81%; p<0.001), thyroid cancer
[27,43,59,65,66,68,69,71] (RR 1.50; 95% CI 1.341.68; I2=0%; p=0.49),
and brain and nervous system cancer [25,26,39,42,52,59,69] (RR
1.41; 95% CI 1.021.93; I2=0%; p=0.97) (Figure 2). Two of six and five
of six sensitivity analyses supported the increased risk of bladder and
thyroid cancer, respectively (Table 2).
The risk of breast, uterine, melanoma, and prostate cancers was
decreased in SLE patients compared with the general population
(Figure 2). Breast cancer risk, reported in ten studies, was decreased
by 13% (RR 0.87; 95% CI 0.761.00; I2=61%; p=0.01)
[27,39,42,47,59,64,65,68,69,72]. The risk of cancer of the uterus,
reported in seven studies, was reduced by 36% (RR 0.64; 95% CI
0.490.83; I2=7%; p=0.37) [27,39,47,59,66,68,69]. Melanoma risk,
reported in six studies, was 31% lower (RR 0.69; 95% CI 0.530.90;
I2=0%; p=0.60) [27,39,42,43,68,69]. Prostate cancer risk, reported in
five studies, was decreased by 20% (RR 0.80; 95% CI 0.650.99; I2=0%;
p=0.43) [27,39,53,59,69]. One of seven (breast), two of six (uterus),
one of four (melanoma), and two of four (prostate) sensitivity analy-
ses supported the decreased cancer risk (Table 2).
For 11 cancers, meta-analyses demonstrated no evidence of
increased risk in SLE patients (Figure 2). This includes two female
malignancies: the composite endpoints ‘all gynaecologic (female)
cancers’ (RR 1.20; 95% CI 0.761.89) [24,43,57] and ovarian cancer
(RR 0.86; 95% CI 0.681.10) [27,42,47,59,64,66,68,69]; six gastroin-
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Figure 2. Forest plots of pooled RRs and strength of evidence for risk of malignancies in people with SLE compared with the general populationa
aEach RR represents a separate meta-analysis. See Supplementary Figure S1 AAH for individual site-specific malignancy outcomes;
bPartial event rate only, number of events, and number of patients were not reported for all studies. CI=confidence interval. NA=not applicable. NHL=non-Hodgkin lymphoma.
RR=risk ratio. SLE=systemic lupus erythematosus.
A.E. Clarke et al. / Seminars in Arthritis and Rheumatism 51 (2021) 12301241 1237[27,39,42,43,59,68,69], colorectal cancer (RR 0.93; 95% CI 0.811.06)
[27,39,59,64,65,68,69], all gastrointestinal cancers (RR 1.15; 95% CI
0.971.37) [39,42,43], rectal cancer (RR 0.83; 95% CI 0.431.58)
[25,51], oral cancer (RR 1.41; 95% CI 0.792.53) [59,64], and small
intestine cancer (RR 1.23; 95% CI 0.314.89) [50,59]; two skin malig-
nancies: non-melanoma (RR 1.24; 95% CI 0.981.57)
[25,39,42,43,59,68] and all skin cancer (RR 1.24; 95% CI
0.413.78) [24,26,56,64]; and kidney cancer (RR 1.77; 95% CI
0.973.25) [25,32,39,42,53,59,68,69]. Twenty-six of 33 sensitivityanalyses supported no evidence of increased risk for these malig-
nancies (Table 2).
In addition to the sensitivity analyses performed, the leave1out
analysis (Table 3) demonstrated no effect on the main result when
removing individual studies for most cancers. Of the cancers with sig-
nificantly increased or decreased risk (n=28), 11 lost significance with
the removal of a single study. All but two cancers (NHL and all respi-
ratory) had an Egger’s test p-value 0.05, indicating no publication
bias (Figure 2).
Table 2
Sensitivity analyses for risk of malignancy in people with SLE compared with the general population: RRs (95% CIs)
Main analysis Least-adjusted
analysis
Date of publication Reporting on fatal and/or non-fatal events Risk of bias Geographical location






Europe North America Asia
All malignancies (composite) 1.18 (1.001.38) 1.19 (1.011.40) 1.39 (1.121.72) 1.10 (0.711.70) 1.27 (1.161.38) 0.56 (0.291.11) 1.33 (1.20 1.47) 1.25 (0.961.62) 1.15 (1.091.21) 1.42 (1.30 1.56)
Increased risk
Reproductive (female) cancers
Cervical 1.66 (1.162.36) 1.72 (1.182.51) 1.11 (0.731.67) 2.12 (1.542.93) .. .. 1.62 (1.331.98) 1.49 (1.072.08) 1.56 (0.554.40) 3.48 (1.508.11)
Vagina/vulva or vulva 3.63 (2.545.20) 3.93 (3.005.15) 4.04 (2.995.46) 1.34 (0.434.14) .. .. 3.49 (1.936.33) 3.91 (1.0714.28) .. ..
Genital (other, female) 3.41 (1.866.23) .. .. .. .. .. .. .. .. ..
Haematologic cancers
NHL 4.32 (3.425.47) 4.56 (3.625.76) 5.61 (3.518.97) 4.56 (3.236.42) .. .. 5.12 (3.926.69) 4.97 (3.287.55) 3.77 (2.156.59) 6.51 (4.299.86)
Hodgkin lymphoma 3.52 (2.016.17) 3.88 (2.575.87) 3.05 (2.024.62) 4.20 (1.5811.16) .. .. 4.36 (1.919.95) 7.63 (5.0311.58) 3.17 (1.795.62) ..
Myeloma 2.10 (1.672.65) 1.82 (1.342.46) 1.59 (1.122.25) 2.58 (1.943.43) .. .. 1.82 (1.152.87) 1.77 (0.953.29) .. ..
All haematologic (composite) 2.71 (1.684.36) .. 2.93 (1.834.68) 2.59 (0.4514.78) 3.34 (2.215.07) 1.47 (0.772.81) 3.72 (2.435.70) 2.67 (1.365.24) 4.45 (2.308.63) ..
All leukaemia (composite) 1.94 (1.562.41) .. 2.35 (1.992.78) .. .. .. 1.77 (1.312.40) 1.96 (1.253.06) 2.16 (1.592.92) ..
Lymphoma 3.03 (2.323.96) 3.01 (3.303.94) .. .. .. .. .. .. .. ..
Myeloid malignancies 2.93 (2.124.05) .. .. .. .. .. .. .. .. ..
Liver and hepatobiliary cancers
Liver 2.81 (1.724.59) .. 2.22 (1.393.54) 4.18 (2.546.89) .. .. 2.90 (1.505.63) 5.11 (3.357.81) .. ..
All hepatobiliary (composite) 2.07 (1.373.12) 1.93 (1.133.30) 2.44 (1.274.69) 2.00 (1.123.55) .. .. 2.12 (1.373.27) 2.65 (1.833.82) .. ..
Liver/gallbladder 1.83 (1.761.90) 1.83 (1.761.90) .. .. .. .. 1.83 (1.761.90) .. .. ..
Respiratory cancers
Lung 1.75 (1.372.24) 1.79 (1.372.33) 1.64 (1.262.13) 2.04 (0.994.22) .. .. 1.90 (1.342.69) 2.21 (1.642.98) 1.66 (1.451.90) 1.39 (1.011.92)
All respiratory (composite) 1.53 (1.112.11) .. .. .. .. .. .. 1.82 (1.412.33) .. ..
Larynx 4.22 (1.979.03) .. .. .. .. .. .. .. .. ..
Oropharynx 7.35 (1.1248.36) 6.73 (1.0344.06) .. .. .. .. .. .. .. ..
Gastrointestinal cancers
Stomach 1.34 (1.051.72) .. 1.45 (1.022.04) 1.42 (0.702.88) .. .. 1.40 (1.051.88) 1.13 (0.632.02) .. 1.37
(0.623.00)
Oesophagus 1.73 (1.042.89) .. 1.65 (1.441.89) .. .. .. 1.467 (0.573.80) 2.46 (0.669.17) .. ..
Colon 1.65 (1.232.22) .. 1.65 (2.222.24) .. .. .. 1.63 (1.212.20) 1.61 (1.182.19) 2.36 (0.727.77) ..
Anal 5.69 (1.6219.94) .. .. .. .. .. .. .. .. ..
Other cancers
Bladder 1.80 (1.043.11) 1.83 (1.073.12) 1.76 (0.913.42) 1.12 (0.502.52) .. .. 2.16 (1.094.27) 1.77 (0.983.21) .. 6.65
(0.18248.86)
Thyroid 1.50 (1.341.68) 1.51 (1.351.69) 2.09 (1.772.46) 1.45 (1.281.65) .. .. 1.47 (1.311.66) 1.35 (0.513.56) .. 1.45
(1.281.65)
Brain and nervous system 1.41 (1.021.93) .. 1.63 (0.654.13) 1.75 (0.973.16) .. .. 1.28 (0.841.93) 1.19 (0.761.88) .. ..
Decreased risk
Reproductive (female) cancers
Breast 0.87 (0.761.00) 0.85 (0.760.94) 0.97 (0.651.43) 1.02 (0.891.17) .. .. 0.92 (0.791.06) 0.90 (0.781.03) 0.92 (0.701.19) 1.17
(0.941.47)
Uterus 0.64 (0.490.83) 0.63 (0.490.80) 0.79 (0.491.28) 0.60 (0.191.97) .. .. 0.66 (0.450.97) 0.90 (0.621.32) .. 0.34
(0.111.02)
Skin cancers
Melanoma 0.69 (0.530.90) .. 0.645 (0.484 0.859) 1.142 (0.40 3.25) .. .. 0.72 (0.481.08) 0.81 (0.501.33) .. ..
Other cancers
Prostate 0.80 (0.650.99) .. 0.80 (0.710.90) .. .. .. 0.96 (0.671.37) 1.68 (0.78 3.63) 0.70 (0.510.95) ..




1.20 (0.761.89) .. .. .. .. .. 1.02 (0.761.37) .. .. ..
Ovarian 0.86 (0.681.10) 0.90 (0.711.14) 0.73 (0.660.81) 1.07 (0.641.78) .. .. 0.90 (0.671.21) 1.07 (0.741.57) 0.83 (0.561.23) 0.94 (0.471.89)
Gastrointestinal cancers
Pancreas 1.26 (0.971.63) 1.44 (1.012.05) 1.34 (0.892.02) 1.93 (1.113.37) .. .. 1.35 (0.961.89) 1.55 (1.012.38) 2.11 (0.627.20) ..
Colorectal 0.93 (0.811.06) .. 0.83 (0.790.87) 1.03 (0.781.34) .. .. 0.97 (0.811.16) 0.89 (0.611.30) 0.91 (0.741.11) 1.07 (0.781.46)
All gastrointestinal
(composite)
1.15 (0.971.37) .. 1.134 (0.951.36) .. .. .. .. .. .. ..
Rectal 0.83 (0.431.58) .. .. .. .. .. .. .. .. ..
Oral 1.41 (0.792.53) .. .. .. .. .. .. .. .. ..
Small intestine 1.23 (0.314.89) .. .. .. .. .. .. .. .. ..
Skin cancers
Non-melanoma 1.24 (0.981.57) 1.25 (1.011.55) 1.50 (1.062.12) 1.07 (0.891.29) .. .. .. 1.29 (0.991.68) .. ..
All skin (composite) 1.24 (0.413.78) .. .. .. .. .. 2.77 (0.779.95) 0.59 (0.0184.54) .. ..
Other cancers
Kidney 1.78 (0.973.25) 1.78 (0.983.24) 2.21 (1.214.06) 1.69 (0.319.22) .. .. 1.67 (0.703.94) 1.83 (0.605.55) 2.16 (1.552.99) ..
Data are reported as RR (95% CIs).



















All malignancies (composite) No impact
Increased risk
Cervical No impact
Vagina/vulva or vulva No impact
Genital (other, female) NA
NHL No impact
Hodgkin lymphoma No impact
Myeloma No impact
All haematologic (composite) No impact




All hepatobiliary (composite) No impact
Liver/gallbladder Loss of significance
Lung No impact
All respiratory (composite) Loss of significance
Larynx Loss of significance
Oropharynx NA
Stomach Loss of significance
Oesophagus Loss of significance
Colon Loss of significance
Anal Loss of significance
Bladder Loss of significance
Thyroid No impact
Brain and nervous system No impact
No evidence of increased risk








Non-melanoma Gain of significance
All skin (composite) No impact
Kidney No impact
Decreased risk
Breast Loss of significance
Uterus No impact
Melanoma Loss of significance
Prostate Loss of significance
NA=not applicable. NHL=non-Hodgkin lymphoma.
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In this meta-analysis evaluating the risk of 40 malignancies, we
identified an 18% increased risk of a composite outcome for all malig-
nancies among patients with SLE compared with the general popula-
tion. We identified 24 site-specific malignancies with increased risk,
including reproductive cancers (cervical, vagina/vulva), all haemato-
logic cancers, all liver and hepatobiliary cancers, all respiratory can-
cers, gastrointestinal cancers (stomach, oesophagus, colon, anal), and
other cancers (bladder, thyroid, brain and nervous system). Of those
with the largest body of evidence (6 studies), NHL and Hodgkin
lymphoma had an increased risk of >3-fold; myeloma and liver >2-
fold; cervical, lung, bladder, and thyroid 1.5-fold; and stomach and
brain >1.3-fold.
Our findings suggest a decreased risk of breast, uterine, mela-
noma, and prostate malignancies in evidence obtained from 5 stud-
ies. There was no evidence of increased risk of 11 site-specific
malignancies: reproductive cancers (all gynaecologic, ovarian), gas-
trointestinal cancers (pancreas, colorectal, all gastrointestinal, rectal,
oral, small intestine), skin cancer (non-melanoma, all skin), and kid-
ney cancer.
The current findings are consistent with previous systematic
reviews that assessed the risk of specific cancer types in SLE patients
compared with the general population [2-10]. Our study has severaladvantages over previous meta-analyses. First, it includes a wider
range of cancer types. Second, it excludes overlapping populations to
ensure patients were evaluated only once, creating improved preci-
sion in RR estimates. Third, it includes recently updated studies with
data from longer follow-up durations. Additionally, our study
presents full sensitivity analyses for each malignancy to support
interpretation of the results.
The increased risk of malignancy observed in SLE patients may be
attributable to various mechanisms including chronic immune stimu-
lation as a result of SLE disease activity [73]; persistent viral infec-
tions, such as EpsteinBarr virus, viral hepatitis, or human papilloma
virus; oxidative stress, which is increased in SLE, can lead to chronic
inflammation and, in turn, contribute to development of fatal comor-
bidities[74], including malignancies [75]; or conventional risk factors,
such as smoking [73]. Immunosuppressive treatment for SLE, such as
cyclophosphamide, may also increase the risk of malignancy, either
directly via immunosuppression and cytotoxicity or indirectly by pro-
moting oncogenic virus emergence [73,76].
Some autoantibody profiles may alter malignancy risk. For exam-
ple, antiphospholipid antibodies are associated with increased risk of
haematologic cancers [77]. We observed an increased risk for all hae-
matologic cancers, including NHL.
Our study identified a decreased risk of hormone-sensitive can-
cers: breast, uterine, and prostate cancers (13%, 36%, and 20%
decreased risk, respectively). This observation could be the result of
autoantibody profiles. Presence of cell-penetrating antidouble-
stranded DNA is associated with a decreased risk of breast cancer
[78]. Decreased risk of hormone-sensitive cancers may also be due to
less exposure to endogenous and/or exogenous hormones, a result of
earlier menopause, and/or avoidance of oral contraceptives or hor-
mone-replacement therapy arising from concerns over adverse out-
comes [79]. It is not known if the increased contact of lupus patients
with the healthcare system leads to increased cancer surveillance,
and potentially early detection of pre-malignant lesions, which may
contribute to the decreased incidence of breast and prostate cancer.
Guidelines recommend that cancer is screened for and managed as
part of the regular monitoring and assessment of lupus patients and
that screening should at least follow cancer screening recommended
for the general population with some guidelines recommending
enhanced screening [80,81]. However, evidence suggests that in
some cases uptake of screening may be lower in patients with SLE
than the general population [82,83].
Our findings suggest a 31% decreased risk of melanoma in patients
with SLE. Because ultraviolent sunlight is known to exacerbate SLE
disease activity [84], patients generally avoid sun over-exposure,
which may provide the benefit of a lower risk of ultraviolet-related
cancers like melanoma.
Our study has some limitations. We identified statistical heteroge-
neity among studies meta-analysed, potentially due to variations in
population characteristics, differences in control group selection, and
variability of risk measures reported. The stability and reliability of
heterogeneity estimates from smaller studies with low event num-
bers should be interpreted carefully [85]. Low event numbers may
decrease precision, with wide CIs for some outcomes. However, we
applied several sensitivity analyses to support interpretation of our
results.
5. Conclusions
This meta-analysis of 40 malignancies demonstrates that patients
with SLE have a marginally increased risk of the composite endpoint
of all malignancies and some site-specific cancer types, with
decreased risk of other cancers, including breast, uterine, melanoma,
and prostate. Malignancy risk may be driven by various mechanisms,
including SLE disease activity; immunomodulatory and immunosup-
pressive therapy; autoantibody profiles; and viral, genetic, or
1240 A.E. Clarke et al. / Seminars in Arthritis and Rheumatism 51 (2021) 12301241environmental factors, for which the evidence base is still evolving.
Further research into the risk profiles and phenotypes of patients
with SLE with increased malignancy risk is warranted to identify
patients at highest risk and to guide development of guidelines and
strategies to mitigate any potential cancer risk in patients with SLE.
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